Grade My Investments
HomeFree Stock Grades › XENE

Xenon Pharmaceuticals Inc. (XENE) Stock Grade

XENE · Healthcare

B
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$3.6B
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
-4612.1%
Return on Equity
Dividend Yield
None

About Xenon Pharmaceuticals Inc.'s fundamentals

Xenon Pharmaceuticals is a $3.6 billion market cap biotechnology company with no dividend yield. The company reported zero revenue growth year-over-year and a significant net loss, resulting in a negative net margin of -4612.1%, indicating substantial operating expenses relative to minimal or break-even revenue. Traditional valuation metrics like P/E ratio and return on equity are not applicable given the company's loss position.

Track XENE free — no credit card required. Live grade + monthly AI report →